Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Most patients with metastatic carcinoma of the prostate have osteoblastic bone metastases and nonmeasurable pelvic disease. These features cause patients to be at high risk for myelosuppression after cytotoxic chemotherapy and make it difficult to evaluate response to treatment. A critical review of larger trials that have sought to assess the role of chemotherapy in treatment of carcinoma of the prostate leads to the following conclusions: (1) Although the aim of treatment is palliation, most trials have tried to evaluate tumor response rather than the more appropriate endpoints of quality and quantity of survival for all treated patients. (2) Criteria that have been used for tumor response are variable and contain large inherent errors; most patients who are labeled as "responders" are described as being "objectively stable," but this category may be a manifestation of slowly progressive disease rather than a response to treatment. (3) There is no evidence that chemotherapy causes a meaningful prolongation of survival. (4) Chemotherapy adds considerable toxicity, and reported trials have not adequately assessed its overall impact on quality of life. Because of these factors there is little evidence that chemotherapy provides palliation for patients with prostatic carcinoma, and it should not be regarded as part of standard management. Selected patients who are symptomatic and no longer responding to hormones may be considered for trials of chemotherapy. Future trials should randomize patients to chemotherapy or supportive care, with assessment of quality and quantity of survival for all randomized patients by an observer who is unaware of the treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sackett, D. L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90012-2 · Cited by 2,075
Controversy in Counting and Attributing Events in Clinical Trials
Sackett, D. L., & Gent, M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197912273012602 · Cited by 413
Cited by
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Self-citationBone metastases: pathophysiology and management policy.
Nielsen, O. S., Munro, A. J., & Tannock, I. F. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.509 · Cited by 486
Self-citationTannock, I., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Self-citationMANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
OH, W. K., & KANTOFF, P. W. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62501-1 · Cited by 260
Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., & Comis, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1754 · Cited by 256
Metadata
- Authors
- Tannock, I. F.
- Venue
- Journal of Clinical Oncology
- Published
- 1985-07
- Volume
- 3
- Issue
- 7
- Pages
- 1013-1021
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1905989945
- Cited by
- 170
- References
- 2
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? https://app.cochat.ai/papers/10.1200/jco.1985.3.7.1013
- The paper
- Tannock, I. F. (1985). Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? Journal of Clinical Oncology. https://doi.org/10.1200/jco.1985.3.7.1013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.